Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$CYTK Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of -$1.50 down -33.93% YoY
• Reported revenue of $28.62M down -57.13% YoY
• Cytokinetics is updating its full year 2026 financial guidance for GAAP combined R&D and SG&A expense to $860 million to $890 million, including $140 million to $130 million of stock-based compensation.